Apollon Formularies leases Jamaican cancer treatment facility

0 18

Apollon Formularies PLC (LON:APOL) said it has signed a long-term lease for its first international cancer institute in the Jamaican capital of Kingston through its affiliate, Apollon Jamaica.

The medical cannabis firm said the new facility will specialise in complementary and alternative medical (CAM) treatments for cancer patients and will allow the company to expand its patient treatment programme for both Jamaican and international medical patients.

READ: Apollon Formularies reopens cannabis centre in Jamaica

Apollon also said the facility with generate additional revenue for the company and allow it to gather patient data on its medical cannabis formulations and provide it with access to Jamaica’s key medical hub.

“We are very proud to be opening this facility and provide Apollon Formularies’ medical cannabis treatments to Jamaicans, as well as patients travelling from international locations. To oversee the facility, we are assembling a team of highly qualified licensed Jamaican physicians, who are experienced in treating cancer patients and are fully knowledgeable in quality, complementary and alternative medical care”, Apollon Jamaica’s chairman and chief executive Paul Burke said in a statement.

“We are very excited to be opening the Apollon International Cancer institute in Jamaica which will enable us to begin treating cancer patients using Apollon’s CAM treatments. This is a milestone for the Company as it is Apollon’s first wholly owned facility, treating patients using the Apollon Formularies medical cannabis formulations. Additionally, it gives us a unique opportunity to gather invaluable data to fully determine the efficacy of Apollon’s formulations directly on patients”, said Apollon CEO Stephen D. Barnhill.

“It is our unique suite of licenses, along with the fact that licensed medical doctors in Jamaica are permitted to write prescriptions for Apollon medical cannabis products using formulations inclusive of THC, that makes the Company unique amongst its listed peers in Europe”, he added.

Leave A Reply

Your email address will not be published.